All-oral chemotherapy regimen tolerable and efficacious for newly diagnosed acute myeloid leukemia
1. In this phase 1-2 trial involving patients with newly diagnosed acute myeloid leukemia who were ineligible for intensive chemotherapy,...
1. In this phase 1-2 trial involving patients with newly diagnosed acute myeloid leukemia who were ineligible for intensive chemotherapy,...
1. The use of enzalutamide (Xtandi) and abiraterone (Zytiga) in metastatic castration-sensitive prostate cancer (mCSPC) was associated with similar overall...
1. Among women with prediabetes following prior gestational diabetes mellitus (GDM), intermittent metformin (Glucophage) in combination with lifestyle modifications was...
1. Erector spinae plane blocks reduced PACU opioid requirements and modestly shortened PACU stay, but did not produce a clinically...
1. Chemotherapy appears to be independently associated with reduced pain severity in advanced pancreatic cancer, reinforcing the importance of routine,...
1. The FDA approved orforglipron (Foundayo) on April 1, 2026, making it the first non-peptide oral GLP-1 receptor agonist cleared...
1. Among children with inflammatory bowel disease, there were no significant differences in serious or outpatient infection risk between initiating...
1. In adult male patients with spermatogenic failure (SPGF), letrozole (Femara) is well tolerated and associated with significantly greater upgrade rates...
1. Leflunomide (LEF) plus prednisone was well tolerated but did not significantly increase clinical remission of Takayasu arteritis (TAK) compared...
1. Administration of perioperative intravenous vitamin C for percutaneous renal biopsy may not reduce the rate of bleeding complications. Evidence...
5-day free trial · cancel anytime
Then $4.99/month. Manage renewal in your account.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
Monthly plan selected: $4.99 /month.
5-day free trial · cancel anytime
Then $4.99/month. Manage renewal in your account.
Yearly plan selected: $49.90 /year.
2 months free · only $4.16/month
Then $49.90/year. Manage renewal in your account.
Already a member? Sign in